BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Five Top CEOs to Watch in 2022

  Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.

  February 23, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  Money on the Move: February 16–22

  More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.

  February 23, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Mnemo Taps Pharma Veteran LaCaze in Quest to Become Global Leader

  Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.

  February 23, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Genetown

  Study Explores Role of Macrophages in Obesity

  Research on obesity is essential, as it can lead to serious health consequences. Researchers are now turning to the immune system for answers about the condition.

  February 23, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  AstraZeneca in the News: EMA Greenlights RSV Vaccine, Leif Johansson Departing

  AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.

  February 23, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Marinus Epilepsy Study Falls Victim to Omicron, Supply Chain Issues

  Marinus Pharmaceuticals reported that its Phase III RAISE trial of IV ganaxolone for status epilepticus will be delayed, thanks to the pandemic.

  February 23, 2022

   · 

  2 min read

   · 

  Mark Terry
• 

  Career Advice

  The Pros and Cons of Working in the Biotech Industry

  Like any field, there are upsides and downsides to working in biotech, and educating yourself can help you make an informed decision if you’re considering a career in this industry.

  February 23, 2022

   · 

  4 min read

   · 

  Alina Zahid
• 

  Genetown

  Study Uncovers Potential Genetic Determinants of Unexplained Child Deaths

  A recent study, published in Genetics in Medicine, concluded that genetic variants contributed to SUPD in 11% of the 352 cases.

  February 23, 2022

   · 

  9 min read

   · 

  Abbey Glasure
• Drug Development

  Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor

  Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today announces that the first patient has been successfully dosed in the phase 1, first-in-human clinical trial of its proprietary CD73 antibody (development code: IBI325) in patients with advanced solid tumor.

  February 23, 2022

   · 

  6 min read
• Bionomics’ Half-Year Report - Feb 24, 2022

  Bionomics Limited, announced its half-year report for the half-year ended 31 December 2021.

  February 23, 2022

   · 

  6 min read